Trial
NCT02556203
Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Bayer
Collaborators
Janssen Research & Development, LLC
Condition
Transcatheter Aortic Valve Replacement
Intervention
Rivaroxaban (Xarelto, BAY59-7939)
Why stopped
Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-01-13